BridgeMD
New treatment option for Hypertension
Official title The Effect of Oral SPM Supplementation on INflammation-induced Vascular Ageing in Obese Hypertensive Patients
ClinicalTrials.gov ID: NCT07038252
What this study is testing
- What it's testing
- Cardiovascular risk factors such as obesity, diabetes, high blood pressure, high cholesterol, or smoking are associated with an increased risk of events such as myocardial infarction, stroke, or peripheral artery disease. Lifestyle and dietary measures, as well as pharmacological treatments, can help correct these risk factors.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 85
You may be able to join if
- Age between 18 and 85 years,.
- Hypertension controlled under pharmacological or non-pharmacological treatment, defined as office BP\< 140/90 mmHg at the Inclusion visit,
- BMI \> 30 kg/m²,
- Stable antihypertensive treatment one month before inclusion (V1),
- Signed informed consent,
You likely can't join if
- Secondary hypertension on the basis of medical history,
- History of stroke in the previous 6 months on the basis of medical history,
- Myocardial infarction in the previous 6 months on the basis of medical history,
- Severe hepatic insufficiency on the basis of medical history,
- Chronic kidney disease (DFG \< 30 ml/min 1.73 according to MDRD method),
- Pregnancy or breast feeding,
See the full eligibility criteria
- Age between 18 and 85 years,.
- Hypertension controlled under pharmacological or non-pharmacological treatment, defined as office BP\< 140/90 mmHg at the Inclusion visit,
- BMI \> 30 kg/m²,
- Stable antihypertensive treatment one month before inclusion (V1),
- Signed informed consent,
- Social security affiliation.
- Secondary hypertension on the basis of medical history,
- History of stroke in the previous 6 months on the basis of medical history,
- Myocardial infarction in the previous 6 months on the basis of medical history,
- Severe hepatic insufficiency on the basis of medical history,
- Chronic kidney disease (DFG \< 30 ml/min 1.73 according to MDRD method),
- Pregnancy or breast feeding,
- Regular treatment with NO-donors or phosphodiesterase inhibitors,
- Inability to comply with protocol requirements,
- Patient under tutorship or / guardianship or/ safeguard of justice, and incapable to give informed consent,
- Patient on AME (state medical aid),
- Participation in another treatment study involving human participants ,
- Allergy to the ultrasound gel,
- Hypersensitivity , allergy, or idiosyncratic reaction to omega-3 acids, fish or soya allergies.
- Chronic inflammatory diseases, on the basis of medical history,
- Chronic anti-inflammatory treatment administered within the past month preceding the Inclusion visit,
- Any supplementation with omega-3 or omega-6 polyunsaturated fatty acids within the past month,
- Life expectancy less than one year.
The study team makes the final eligibility decision.
Where it's taking place
- Paris, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Paris, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.